Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
With the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRAS G12C in the current first line of treatment. We compared overall survival (OS) of patients...
Saved in:
| Published in | JTO clinical and research reports Vol. 4; no. 9; p. 100543 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier Inc
01.09.2023
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2666-3643 2666-3643 |
| DOI | 10.1016/j.jtocrr.2023.100543 |
Cover
| Abstract | With the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRAS G12C in the current first line of treatment. We compared overall survival (OS) of patients with stage IV KRAS G12C-mutated NSCLC to those with a KRAS non-G12C mutation in a first-line setting of (chemo)immunotherapy.
This nationwide population-based study used real-world data from The Netherlands Cancer Registry. We selected patients with stage IV KRAS-mutated lung adenocarcinoma diagnosed in 2019 to 2020 who received first-line (chemo-)immunotherapy. Primary outcome was OS.
From 28,120 registered patients with lung cancer, 1185 were selected with a KRAS mutation, of which 494 had a KRAS G12C mutation. Median OS was 15.5 months (95% confidence interval [CI]: 13.6–18.4) for KRAS G12C versus 14.0 months (95% CI:11.2–15.7) for KRAS non-G12C (p = 0.67). In multivariable analysis, KRAS subtype was not associated with OS (hazard ratio = 0.95, 95% CI: 0.82–1.10). For the subgroup with programmed death-ligand 1 at 0% to 49% who received chemoimmunotherapy, median OS was 13.3 months (95% CI: 10.5–15.2) for G12C and 9.8 months (95% CI: 8.6–11.3) for non-G12C (p = 0.48). For the subgroup with programmed death-ligand 1 more than or equal to 50% who received monoimmunotherapy, the median OS was 22.0 months (95% CI: 18.4–27.3) for G12C and 18.9 months (95% CI: 14.9–25.2) for non-G12C (p = 0.36).
There was no influence of KRAS subtype (G12C versus non-G12C) on OS in patients with KRAS-mutated stage IV NSCLC treated with first-line (chemo)immunotherapy. |
|---|---|
| AbstractList | With the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRAS G12C in the current first line of treatment. We compared overall survival (OS) of patients with stage IV KRAS G12C-mutated NSCLC to those with a KRAS non-G12C mutation in a first-line setting of (chemo)immunotherapy.
This nationwide population-based study used real-world data from The Netherlands Cancer Registry. We selected patients with stage IV KRAS-mutated lung adenocarcinoma diagnosed in 2019 to 2020 who received first-line (chemo-)immunotherapy. Primary outcome was OS.
From 28,120 registered patients with lung cancer, 1185 were selected with a KRAS mutation, of which 494 had a KRAS G12C mutation. Median OS was 15.5 months (95% confidence interval [CI]: 13.6–18.4) for KRAS G12C versus 14.0 months (95% CI:11.2–15.7) for KRAS non-G12C (p = 0.67). In multivariable analysis, KRAS subtype was not associated with OS (hazard ratio = 0.95, 95% CI: 0.82–1.10). For the subgroup with programmed death-ligand 1 at 0% to 49% who received chemoimmunotherapy, median OS was 13.3 months (95% CI: 10.5–15.2) for G12C and 9.8 months (95% CI: 8.6–11.3) for non-G12C (p = 0.48). For the subgroup with programmed death-ligand 1 more than or equal to 50% who received monoimmunotherapy, the median OS was 22.0 months (95% CI: 18.4–27.3) for G12C and 18.9 months (95% CI: 14.9–25.2) for non-G12C (p = 0.36).
There was no influence of KRAS subtype (G12C versus non-G12C) on OS in patients with KRAS-mutated stage IV NSCLC treated with first-line (chemo)immunotherapy. AbstractIntroductionWith the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRAS G12C in the current first line of treatment. We compared overall survival (OS) of patients with stage IV KRAS G12C-mutated NSCLC to those with a KRAS non-G12C mutation in a first-line setting of (chemo)immunotherapy. MethodsThis nationwide population-based study used real-world data from The Netherlands Cancer Registry. We selected patients with stage IV KRAS-mutated lung adenocarcinoma diagnosed in 2019 to 2020 who received first-line (chemo-)immunotherapy. Primary outcome was OS. ResultsFrom 28,120 registered patients with lung cancer, 1185 were selected with a KRAS mutation, of which 494 had a KRAS G12C mutation. Median OS was 15.5 months (95% confidence interval [CI]: 13.6–18.4) for KRAS G12C versus 14.0 months (95% CI:11.2–15.7) for KRAS non-G12C ( p = 0.67). In multivariable analysis, KRAS subtype was not associated with OS (hazard ratio = 0.95, 95% CI: 0.82–1.10). For the subgroup with programmed death-ligand 1 at 0% to 49% who received chemoimmunotherapy, median OS was 13.3 months (95% CI: 10.5–15.2) for G12C and 9.8 months (95% CI: 8.6–11.3) for non-G12C ( p = 0.48). For the subgroup with programmed death-ligand 1 more than or equal to 50% who received monoimmunotherapy, the median OS was 22.0 months (95% CI: 18.4–27.3) for G12C and 18.9 months (95% CI: 14.9–25.2) for non-G12C ( p = 0.36). ConclusionsThere was no influence of KRAS subtype (G12C versus non-G12C) on OS in patients with KRAS-mutated stage IV NSCLC treated with first-line (chemo)immunotherapy. With the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRAS G12C in the current first line of treatment. We compared overall survival (OS) of patients with stage IV KRAS G12C-mutated NSCLC to those with a KRAS non-G12C mutation in a first-line setting of (chemo)immunotherapy.IntroductionWith the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRAS G12C in the current first line of treatment. We compared overall survival (OS) of patients with stage IV KRAS G12C-mutated NSCLC to those with a KRAS non-G12C mutation in a first-line setting of (chemo)immunotherapy.This nationwide population-based study used real-world data from The Netherlands Cancer Registry. We selected patients with stage IV KRAS-mutated lung adenocarcinoma diagnosed in 2019 to 2020 who received first-line (chemo-)immunotherapy. Primary outcome was OS.MethodsThis nationwide population-based study used real-world data from The Netherlands Cancer Registry. We selected patients with stage IV KRAS-mutated lung adenocarcinoma diagnosed in 2019 to 2020 who received first-line (chemo-)immunotherapy. Primary outcome was OS.From 28,120 registered patients with lung cancer, 1185 were selected with a KRAS mutation, of which 494 had a KRAS G12C mutation. Median OS was 15.5 months (95% confidence interval [CI]: 13.6-18.4) for KRAS G12C versus 14.0 months (95% CI:11.2-15.7) for KRAS non-G12C (p = 0.67). In multivariable analysis, KRAS subtype was not associated with OS (hazard ratio = 0.95, 95% CI: 0.82-1.10). For the subgroup with programmed death-ligand 1 at 0% to 49% who received chemoimmunotherapy, median OS was 13.3 months (95% CI: 10.5-15.2) for G12C and 9.8 months (95% CI: 8.6-11.3) for non-G12C (p = 0.48). For the subgroup with programmed death-ligand 1 more than or equal to 50% who received monoimmunotherapy, the median OS was 22.0 months (95% CI: 18.4-27.3) for G12C and 18.9 months (95% CI: 14.9-25.2) for non-G12C (p = 0.36).ResultsFrom 28,120 registered patients with lung cancer, 1185 were selected with a KRAS mutation, of which 494 had a KRAS G12C mutation. Median OS was 15.5 months (95% confidence interval [CI]: 13.6-18.4) for KRAS G12C versus 14.0 months (95% CI:11.2-15.7) for KRAS non-G12C (p = 0.67). In multivariable analysis, KRAS subtype was not associated with OS (hazard ratio = 0.95, 95% CI: 0.82-1.10). For the subgroup with programmed death-ligand 1 at 0% to 49% who received chemoimmunotherapy, median OS was 13.3 months (95% CI: 10.5-15.2) for G12C and 9.8 months (95% CI: 8.6-11.3) for non-G12C (p = 0.48). For the subgroup with programmed death-ligand 1 more than or equal to 50% who received monoimmunotherapy, the median OS was 22.0 months (95% CI: 18.4-27.3) for G12C and 18.9 months (95% CI: 14.9-25.2) for non-G12C (p = 0.36).There was no influence of KRAS subtype (G12C versus non-G12C) on OS in patients with KRAS-mutated stage IV NSCLC treated with first-line (chemo)immunotherapy.ConclusionsThere was no influence of KRAS subtype (G12C versus non-G12C) on OS in patients with KRAS-mutated stage IV NSCLC treated with first-line (chemo)immunotherapy. Introduction: With the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRAS G12C in the current first line of treatment. We compared overall survival (OS) of patients with stage IV KRAS G12C-mutated NSCLC to those with a KRAS non-G12C mutation in a first-line setting of (chemo)immunotherapy. Methods: This nationwide population-based study used real-world data from The Netherlands Cancer Registry. We selected patients with stage IV KRAS-mutated lung adenocarcinoma diagnosed in 2019 to 2020 who received first-line (chemo-)immunotherapy. Primary outcome was OS. Results: From 28,120 registered patients with lung cancer, 1185 were selected with a KRAS mutation, of which 494 had a KRAS G12C mutation. Median OS was 15.5 months (95% confidence interval [CI]: 13.6–18.4) for KRAS G12C versus 14.0 months (95% CI:11.2–15.7) for KRAS non-G12C (p = 0.67). In multivariable analysis, KRAS subtype was not associated with OS (hazard ratio = 0.95, 95% CI: 0.82–1.10). For the subgroup with programmed death-ligand 1 at 0% to 49% who received chemoimmunotherapy, median OS was 13.3 months (95% CI: 10.5–15.2) for G12C and 9.8 months (95% CI: 8.6–11.3) for non-G12C (p = 0.48). For the subgroup with programmed death-ligand 1 more than or equal to 50% who received monoimmunotherapy, the median OS was 22.0 months (95% CI: 18.4–27.3) for G12C and 18.9 months (95% CI: 14.9–25.2) for non-G12C (p = 0.36). Conclusions: There was no influence of KRAS subtype (G12C versus non-G12C) on OS in patients with KRAS-mutated stage IV NSCLC treated with first-line (chemo)immunotherapy. |
| ArticleNumber | 100543 |
| Author | Swart, Esther M. Damhuis, Ronald A.M. Aarts, Mieke J. van Geffen, Wouter H. Kunst, Peter W.A. Noordhof, Anneloes L. Hendriks, Lizza E.L. |
| Author_xml | – sequence: 1 givenname: Anneloes L. surname: Noordhof fullname: Noordhof, Anneloes L. organization: Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands – sequence: 2 givenname: Esther M. surname: Swart fullname: Swart, Esther M. organization: Department of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands – sequence: 3 givenname: Ronald A.M. surname: Damhuis fullname: Damhuis, Ronald A.M. organization: Department of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands – sequence: 4 givenname: Lizza E.L. surname: Hendriks fullname: Hendriks, Lizza E.L. organization: Department of Respiratory Medicine, GROW-School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands – sequence: 5 givenname: Peter W.A. surname: Kunst fullname: Kunst, Peter W.A. organization: Department of Respiratory Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands – sequence: 6 givenname: Mieke J. surname: Aarts fullname: Aarts, Mieke J. organization: Department of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands – sequence: 7 givenname: Wouter H. orcidid: 0000-0002-5976-0974 surname: van Geffen fullname: van Geffen, Wouter H. email: wouter.van.geffen@mcl.nl organization: Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands |
| BookMark | eNqVklFv0zAQxyM0JMbYN-DBj7yk2E7iJAiBpghGRRloLezRcuxL65LaxXYm9UPwnXGaCTEkNPFk6-7-v7Pv_k-TE2MNJMlzgmcEE_ZyO9sGK52bUUyzGMJFnj1KTiljLM1Ynp38cX-SnHu_xRjTgpCyoqfJzy_Oro31QUs03-17LUXQ1iDboY_XF0t0SWiDPg1himqDBLoG0ac31vXqWJIes6DQMog1oPk3dLVsFg1q7Ma6gFYOjtkbHTaxw24wNmzAif1hpK02gK5gDPTCKP8sedyJ3sP53XmWfH3_btV8SBefL-fNxSKVjBQhlTVTkpalqgUjVdfWgDMJWUc6QgTkIs8rRutC4bqjbd0qXBUC6pJVNWFF3XbZWTKfuMqKLd87vRPuwK3Q_Biwbs2FiyPpgQNtc4IVbnGZ5wUmomuJlKpimKgCSxlZbyfWfmh3oCSY4ER_D3o_Y_SGr-0tJzgv45vySHhxR3D2xwA-8J32Evo4ErCD5zT-hmKckSKW5lOpdNZ7B93vPgTz0Q58yyc78NEOfLJDlL36Syb1tNL4It0_JH4ziSFu5FaD415qMBKUdiBDHJn-X4DstYlO67_DAfzWDs7EbXPCPeWYL0e7jm6lWXRqxUbA638DHu7_C7OT_lQ |
| CitedBy_id | crossref_primary_10_3389_fonc_2024_1517049 crossref_primary_10_1080_13696998_2024_2437324 crossref_primary_10_1111_1759_7714_15413 |
| Cites_doi | 10.1586/17476348.2016.1115349 10.1016/S0140-6736(18)32409-7 10.1016/j.ebiom.2019.02.049 10.21037/tlcr-20-958 10.1056/NEJMoa2103695 10.1056/NEJMoa1801005 10.1016/j.jtho.2019.01.020 10.1016/j.lungcan.2022.03.015 10.1093/annonc/mdz453.001 10.3390/cancers13174294 10.1016/j.lungcan.2021.04.001 10.1016/j.jtho.2019.01.011 10.1097/JTO.0000000000000432 10.1016/j.lungcan.2021.02.005 10.1016/j.lungcan.2022.10.005 10.1038/s41586-019-1694-1 10.1093/annonc/mdz167 10.1016/j.ctrv.2020.101978 10.3389/fonc.2019.00953 10.1056/NEJMc2030638 10.1016/j.ctrv.2020.101974 10.1016/S0140-6736(23)00221-0 10.1021/acs.jmedchem.9b01180 10.1158/0008-5472.CAN-19-3682 10.1016/j.annonc.2021.06.001 10.1016/j.cllc.2021.04.010 10.1093/annonc/mdz288 10.1016/j.jtho.2018.12.013 10.1016/j.lungcan.2021.12.021 10.1158/1078-0432.CCR-20-4023 10.1016/j.annonc.2022.08.051 10.1016/j.lungcan.2019.05.015 10.1158/1078-0432.CCR-17-1841 10.1158/2159-8290.CD-19-1167 10.1038/s41573-020-0068-6 10.1093/annonc/mdt205 10.1056/NEJMoa2204619 10.1016/j.lungcan.2021.05.026 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors The Authors 2023 The Authors. 2023 The Authors 2023 |
| Copyright_xml | – notice: 2023 The Authors – notice: The Authors – notice: 2023 The Authors. – notice: 2023 The Authors 2023 |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1016/j.jtocrr.2023.100543 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2666-3643 |
| EndPage | 100543 |
| ExternalDocumentID | oai_doaj_org_article_e2b410d0b0744501afb1ccd8601d50cc PMC10477684 10_1016_j_jtocrr_2023_100543 S2666364323000863 1_s2_0_S2666364323000863 |
| GroupedDBID | .1- .FO 0R~ 1P~ 53G AAEDW AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL RPM Z5R AAHOK AFCTW NCXOZ 6I. AAFTH AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c615t-c96dc277d9a618fb9e03ce3f1f11ae4a4486295d09f2b9bd085ae976891659bf3 |
| IEDL.DBID | DOA |
| ISSN | 2666-3643 |
| IngestDate | Wed Aug 27 01:29:48 EDT 2025 Thu Aug 21 18:36:40 EDT 2025 Fri Sep 05 03:03:44 EDT 2025 Thu Apr 24 22:59:02 EDT 2025 Tue Jul 01 03:31:44 EDT 2025 Sat Sep 30 17:10:48 EDT 2023 Tue Feb 25 19:54:55 EST 2025 Tue Aug 26 19:33:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | Non–small cell lung cancer Kirsten rat sarcoma KRAS G12C (Chemo-)immunotherapy |
| Language | English |
| License | This is an open access article under the CC BY license. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c615t-c96dc277d9a618fb9e03ce3f1f11ae4a4486295d09f2b9bd085ae976891659bf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5976-0974 |
| OpenAccessLink | https://doaj.org/article/e2b410d0b0744501afb1ccd8601d50cc |
| PQID | 2862200315 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e2b410d0b0744501afb1ccd8601d50cc pubmedcentral_primary_oai_pubmedcentral_nih_gov_10477684 proquest_miscellaneous_2862200315 crossref_primary_10_1016_j_jtocrr_2023_100543 crossref_citationtrail_10_1016_j_jtocrr_2023_100543 elsevier_sciencedirect_doi_10_1016_j_jtocrr_2023_100543 elsevier_clinicalkeyesjournals_1_s2_0_S2666364323000863 elsevier_clinicalkey_doi_10_1016_j_jtocrr_2023_100543 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-09-01 |
| PublicationDateYYYYMMDD | 2023-09-01 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | JTO clinical and research reports |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Gandhi, Rodríguez-Abreu, Gadgeel (bib40) 2018; 378 Wahl, Dai, Emdal (bib42) 2021; 13 Friedlaender, Drilon, Weiss, Banna, Addeo (bib6) 2020; 85 Nassar, Adib, Kwiatkowski (bib50) 2021; 384 De Langen, Johnson, Mazieres (bib21) 2023; 401 Yu, Du, Mekhail, Socinski, Chang (bib31) 2021; 22 Gijtenbeek, Damhuis, van der Wekken, Hendriks, Groen, van Geffen (bib36) 2023; 27 Prior, Hood, Hartley (bib4) 2020; 80 bib35 Canon, Rex, Saiki (bib15) 2019; 575 Moore, Rosenberg, McCormick, Malek (bib1) 2020; 19 Justeau, Huchot, Simonneau (bib34) 2022; 174 Luo, Ostrem, Pellini (bib7) 2022; 42 Arbour, Ricciuti, Rizvi (bib26) 2021; 39 Jänne, Riely, Gadgeel (bib19) 2022; 387 Dearden, Stevens, Wu, Blowers (bib49) 2013; 24 Nakajima, Ren, Vallejo (bib33) 2022; 40 Garassino, Gadgeel, Novello (bib39) 2022; 4 Ricciuti, Leonardi, Metro (bib12) 2016; 10 Hallin, Engstrom, Hargi (bib17) 2020; 10 Ruppert, Beau-Faller, Debieuvre (bib10) 2020; 1 Lanman, Allen, Allen (bib16) 2020; 63 Frost, Kollmeier, Vollbrecht (bib27) 2021; 10 El Osta, Behera, Kim (bib45) 2019; 14 Scheffler, Ihle, Hein (bib46) 2019; 14 Spira, Tu, Aggarwal (bib48) 2021; 159 Skoulidis, Li, Dy (bib18) 2021; 384 Suk Heist, Yu, Donderici (bib47) 2021; 39 Arbour, Rizvi, Plodkowski (bib9) 2021; 27 Nagasaka, Li, Sukari, Ou, Al-Hallak, Azmi (bib11) 2020; 84 Yang, Liang, Schmid, Peng (bib13) 2019; 9 Kartolo, Feilotter, Hopman, Fung, Robinson (bib28) 2021; 27 Herbst, Lopes, Kowalski (bib37) 2019; 30 Adderley, Blackhall, Lindsay (bib14) 2019; 41 Jeanson, Tomasini, Souquet-Bressand (bib25) 2019; 14 Mazieres, Drilon, Lusque (bib30) 2019; 30 Mok, Wu, Kudaba (bib38) 2019; 393 Rohatgi, Govindan (bib5) 2021; 165 bib23 bib22 Johnson, de Langen, Waterhouse (bib20) 2022; 33 Aredo, Padda, Kunder (bib43) 2019; 133 Negrao, Skoulidis, Montesion (bib29) 2021; 9 Arbour, Jordan, Kim (bib44) 2018; 24 Reck, Carbone, Garassino, Barlesi (bib3) 2021; 32 Garcia, van Kempen, Kuijpers, Schuuring, Willems, van der Wekken (bib2) 2022; 167 Sebastian, Eberhardt, Hoffknecht (bib41) 2021; 154 Yu, Sima, Shen (bib8) 2015; 10 Aguilar, Ricciuti, Gainor (bib32) 2019; 30 Noordhof, Damhuis, Hendriks (bib24) 2021; 155 Spira (10.1016/j.jtocrr.2023.100543_bib48) 2021; 159 Negrao (10.1016/j.jtocrr.2023.100543_bib29) 2021; 9 Gandhi (10.1016/j.jtocrr.2023.100543_bib40) 2018; 378 Friedlaender (10.1016/j.jtocrr.2023.100543_bib6) 2020; 85 Rohatgi (10.1016/j.jtocrr.2023.100543_bib5) 2021; 165 Aredo (10.1016/j.jtocrr.2023.100543_bib43) 2019; 133 Skoulidis (10.1016/j.jtocrr.2023.100543_bib18) 2021; 384 Dearden (10.1016/j.jtocrr.2023.100543_bib49) 2013; 24 Prior (10.1016/j.jtocrr.2023.100543_bib4) 2020; 80 Arbour (10.1016/j.jtocrr.2023.100543_bib9) 2021; 27 Noordhof (10.1016/j.jtocrr.2023.100543_bib24) 2021; 155 Scheffler (10.1016/j.jtocrr.2023.100543_bib46) 2019; 14 Adderley (10.1016/j.jtocrr.2023.100543_bib14) 2019; 41 Jeanson (10.1016/j.jtocrr.2023.100543_bib25) 2019; 14 Sebastian (10.1016/j.jtocrr.2023.100543_bib41) 2021; 154 Suk Heist (10.1016/j.jtocrr.2023.100543_bib47) 2021; 39 Lanman (10.1016/j.jtocrr.2023.100543_bib16) 2020; 63 Garcia (10.1016/j.jtocrr.2023.100543_bib2) 2022; 167 Canon (10.1016/j.jtocrr.2023.100543_bib15) 2019; 575 Yu (10.1016/j.jtocrr.2023.100543_bib31) 2021; 22 Aguilar (10.1016/j.jtocrr.2023.100543_bib32) 2019; 30 Wahl (10.1016/j.jtocrr.2023.100543_bib42) 2021; 13 Nagasaka (10.1016/j.jtocrr.2023.100543_bib11) 2020; 84 Herbst (10.1016/j.jtocrr.2023.100543_bib37) 2019; 30 Ricciuti (10.1016/j.jtocrr.2023.100543_bib12) 2016; 10 Moore (10.1016/j.jtocrr.2023.100543_bib1) 2020; 19 Gijtenbeek (10.1016/j.jtocrr.2023.100543_bib36) 2023; 27 Jänne (10.1016/j.jtocrr.2023.100543_bib19) 2022; 387 Mok (10.1016/j.jtocrr.2023.100543_bib38) 2019; 393 Nassar (10.1016/j.jtocrr.2023.100543_bib50) 2021; 384 Reck (10.1016/j.jtocrr.2023.100543_bib3) 2021; 32 Yang (10.1016/j.jtocrr.2023.100543_bib13) 2019; 9 Arbour (10.1016/j.jtocrr.2023.100543_bib44) 2018; 24 Arbour (10.1016/j.jtocrr.2023.100543_bib26) 2021; 39 Yu (10.1016/j.jtocrr.2023.100543_bib8) 2015; 10 Kartolo (10.1016/j.jtocrr.2023.100543_bib28) 2021; 27 De Langen (10.1016/j.jtocrr.2023.100543_bib21) 2023; 401 Justeau (10.1016/j.jtocrr.2023.100543_bib34) 2022; 174 Ruppert (10.1016/j.jtocrr.2023.100543_bib10) 2020; 1 Hallin (10.1016/j.jtocrr.2023.100543_bib17) 2020; 10 Garassino (10.1016/j.jtocrr.2023.100543_bib39) 2022; 4 El Osta (10.1016/j.jtocrr.2023.100543_bib45) 2019; 14 Luo (10.1016/j.jtocrr.2023.100543_bib7) 2022; 42 Frost (10.1016/j.jtocrr.2023.100543_bib27) 2021; 10 Johnson (10.1016/j.jtocrr.2023.100543_bib20) 2022; 33 Mazieres (10.1016/j.jtocrr.2023.100543_bib30) 2019; 30 Nakajima (10.1016/j.jtocrr.2023.100543_bib33) 2022; 40 |
| References_xml | – volume: 10 start-page: 737 year: 2021 end-page: 752 ident: bib27 article-title: KRAS publication-title: Transl Lung Cancer Res – volume: 9 year: 2021 ident: bib29 article-title: Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer publication-title: J Immunother Cancer – volume: 174 start-page: 45 year: 2022 end-page: 49 ident: bib34 article-title: Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy publication-title: Lung Cancer – volume: 41 start-page: 711 year: 2019 end-page: 716 ident: bib14 article-title: KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition publication-title: EBioMedicine – volume: 4 year: 2022 ident: bib39 article-title: Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic NSCLC publication-title: JTO Clin Res Rep – volume: 10 start-page: 431 year: 2015 end-page: 437 ident: bib8 article-title: Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas publication-title: J Thorac Oncol – volume: 14 start-page: 1095 year: 2019 end-page: 1101 ident: bib25 article-title: Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC) publication-title: J Thorac Oncol – volume: 133 start-page: 144 year: 2019 end-page: 150 ident: bib43 article-title: Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes publication-title: Lung Cancer – volume: 378 start-page: 2078 year: 2018 end-page: 2092 ident: bib40 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N Engl J Med – volume: 30 start-page: 1321 year: 2019 end-page: 1328 ident: bib30 article-title: Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry publication-title: Ann Oncol – volume: 10 start-page: 53 year: 2016 end-page: 68 ident: bib12 article-title: Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications publication-title: Expert Rev Respir Med – volume: 401 start-page: 733 year: 2023 end-page: 746 ident: bib21 article-title: Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS publication-title: Lancet – volume: 14 start-page: 876 year: 2019 end-page: 889 ident: bib45 article-title: Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience publication-title: J Thorac Oncol – volume: 33 start-page: S1417 year: 2022 end-page: S1418 ident: bib20 article-title: LBA10 - Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study publication-title: Ann Oncol – volume: 32 start-page: 1101 year: 2021 end-page: 1110 ident: bib3 article-title: Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches publication-title: Ann Oncol – volume: 384 start-page: 2371 year: 2021 end-page: 2381 ident: bib18 article-title: Sotorasib for lung cancers with KRAS p.G12C Mutation publication-title: N Engl J Med – volume: 39 year: 2021 ident: bib26 article-title: Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer publication-title: J Clin Oncol – volume: 165 start-page: 28 year: 2021 end-page: 33 ident: bib5 article-title: Targeting KRAS G12C mutation in lung adenocarcinoma publication-title: Lung Cancer – volume: 1 year: 2020 ident: bib10 article-title: Outcomes of patients with advanced NSCLC from the intergroupe francophone de cancérologie thoracique biomarkers France Study by publication-title: JTO Clin Res Rep – volume: 42 start-page: 1 year: 2022 end-page: 11 ident: bib7 article-title: Overcoming publication-title: Am Soc Clin Oncol Educ Book – volume: 85 year: 2020 ident: bib6 article-title: KRAS as a druggable target in NSCLC: rising like a phoenix after decades of development failures publication-title: Cancer Treat Rev – volume: 80 start-page: 2669 year: 2020 end-page: 2974 ident: bib4 article-title: The frequency of Ras mutations in cancer publication-title: Cancer Res – ident: bib23 article-title: Lumykras – volume: 13 start-page: 4294 year: 2021 ident: bib42 article-title: The prognostic effect of publication-title: Cancers (Basel) – volume: 9 start-page: 953 year: 2019 ident: bib13 article-title: New horizons in publication-title: Front Oncol – volume: 63 start-page: 52 year: 2020 end-page: 65 ident: bib16 article-title: Discovery of a covalent inhibitor of KRAS publication-title: J Med Chem – volume: 155 start-page: 163 year: 2021 end-page: 169 ident: bib24 article-title: Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy publication-title: Lung Cancer – volume: 167 start-page: 1 year: 2022 end-page: 7 ident: bib2 article-title: Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study publication-title: Lung Cancer – volume: 84 year: 2020 ident: bib11 article-title: KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? publication-title: Cancer Treat Rev – volume: 384 start-page: 185 year: 2021 end-page: 187 ident: bib50 article-title: Distribution of KRAS publication-title: N Engl J Med – volume: 24 start-page: 2371 year: 2013 end-page: 2376 ident: bib49 article-title: Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) publication-title: Ann Oncol – volume: 387 start-page: 120 year: 2022 end-page: 131 ident: bib19 article-title: Adagrasib in non-small-cell lung cancer harboring a publication-title: N Engl J Med – volume: 30 start-page: 1653 year: 2019 end-page: 1659 ident: bib32 article-title: Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression publication-title: Ann Oncol – volume: 14 start-page: 606 year: 2019 end-page: 616 ident: bib46 article-title: K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways publication-title: J Thorac Oncol – volume: 40 year: 2022 ident: bib33 article-title: Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis publication-title: J Clin Oncol – volume: 22 start-page: e856 year: 2021 end-page: e858 ident: bib31 article-title: Adverse overall survival impact of PD-L1 positivity in patients with KRAS G12C mutation is abolished by the immunotherapy publication-title: Clin Lung Cancer – volume: 24 start-page: 334 year: 2018 end-page: 340 ident: bib44 article-title: Effects of co-occurring genomic alterations on outcomes in patients with publication-title: Clin Cancer Res – volume: 30 start-page: xi63 year: 2019 end-page: xi64 ident: bib37 article-title: LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 publication-title: Ann Oncol – volume: 393 start-page: 1819 year: 2019 end-page: 1830 ident: bib38 article-title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial publication-title: Lancet – volume: 19 start-page: 533 year: 2020 end-page: 552 ident: bib1 article-title: RAS-targeted therapies: is the undruggable drugged? [published correction appears in publication-title: Nat Rev Drug Discov – volume: 159 start-page: 1 year: 2021 end-page: 9 ident: bib48 article-title: A retrospective observational study of the natural history of advanced non–small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease publication-title: Lung Cancer – ident: bib22 article-title: FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC – volume: 39 year: 2021 ident: bib47 article-title: Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort publication-title: J Clin Oncol – volume: 27 year: 2021 ident: bib28 article-title: A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors publication-title: Cancer Treat Res Commun – volume: 10 start-page: 54 year: 2020 end-page: 71 ident: bib17 article-title: The KRAS publication-title: Cancer Discov – volume: 154 start-page: 51 year: 2021 end-page: 61 ident: bib41 article-title: KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315) publication-title: Lung Cancer – volume: 27 start-page: 2209 year: 2021 end-page: 2215 ident: bib9 article-title: Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer publication-title: Clin Cancer Res – volume: 575 start-page: 217 year: 2019 end-page: 223 ident: bib15 article-title: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity publication-title: Nature – volume: 27 year: 2023 ident: bib36 article-title: Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in the Netherlands: a retrospective, nationwide registry study publication-title: Lancet Reg Heal Eur – ident: bib35 article-title: Netherlands Cancer Registry – volume: 27 year: 2023 ident: 10.1016/j.jtocrr.2023.100543_bib36 article-title: Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in the Netherlands: a retrospective, nationwide registry study publication-title: Lancet Reg Heal Eur – volume: 10 start-page: 53 year: 2016 ident: 10.1016/j.jtocrr.2023.100543_bib12 article-title: Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications publication-title: Expert Rev Respir Med doi: 10.1586/17476348.2016.1115349 – volume: 42 start-page: 1 year: 2022 ident: 10.1016/j.jtocrr.2023.100543_bib7 article-title: Overcoming KRAS -mutant lung cancer publication-title: Am Soc Clin Oncol Educ Book – volume: 393 start-page: 1819 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib38 article-title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)32409-7 – volume: 41 start-page: 711 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib14 article-title: KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition publication-title: EBioMedicine doi: 10.1016/j.ebiom.2019.02.049 – volume: 10 start-page: 737 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib27 article-title: KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr-20-958 – volume: 384 start-page: 2371 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib18 article-title: Sotorasib for lung cancers with KRAS p.G12C Mutation publication-title: N Engl J Med doi: 10.1056/NEJMoa2103695 – volume: 378 start-page: 2078 year: 2018 ident: 10.1016/j.jtocrr.2023.100543_bib40 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1801005 – volume: 14 start-page: 876 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib45 article-title: Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.01.020 – volume: 27 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib28 article-title: A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors publication-title: Cancer Treat Res Commun – volume: 167 start-page: 1 year: 2022 ident: 10.1016/j.jtocrr.2023.100543_bib2 article-title: Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study publication-title: Lung Cancer doi: 10.1016/j.lungcan.2022.03.015 – volume: 40 issue: suppl 16 year: 2022 ident: 10.1016/j.jtocrr.2023.100543_bib33 article-title: Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis publication-title: J Clin Oncol – volume: 30 start-page: xi63 issue: suppl 11 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib37 article-title: LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 publication-title: Ann Oncol doi: 10.1093/annonc/mdz453.001 – volume: 13 start-page: 4294 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib42 article-title: The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: a Norwegian multicentre study publication-title: Cancers (Basel) doi: 10.3390/cancers13174294 – volume: 155 start-page: 163 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib24 article-title: Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy publication-title: Lung Cancer doi: 10.1016/j.lungcan.2021.04.001 – volume: 14 start-page: 1095 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib25 article-title: Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC) publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.01.011 – volume: 10 start-page: 431 year: 2015 ident: 10.1016/j.jtocrr.2023.100543_bib8 article-title: Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000432 – volume: 154 start-page: 51 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib41 article-title: KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315) publication-title: Lung Cancer doi: 10.1016/j.lungcan.2021.02.005 – volume: 174 start-page: 45 year: 2022 ident: 10.1016/j.jtocrr.2023.100543_bib34 article-title: Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy publication-title: Lung Cancer doi: 10.1016/j.lungcan.2022.10.005 – volume: 1 year: 2020 ident: 10.1016/j.jtocrr.2023.100543_bib10 article-title: Outcomes of patients with advanced NSCLC from the intergroupe francophone de cancérologie thoracique biomarkers France Study by KRAS mutation subtypes publication-title: JTO Clin Res Rep – volume: 575 start-page: 217 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib15 article-title: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity publication-title: Nature doi: 10.1038/s41586-019-1694-1 – volume: 39 issue: suppl 15 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib47 article-title: Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort publication-title: J Clin Oncol – volume: 30 start-page: 1321 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib30 article-title: Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry publication-title: Ann Oncol doi: 10.1093/annonc/mdz167 – volume: 39 issue: suppl 15 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib26 article-title: Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer publication-title: J Clin Oncol – volume: 85 year: 2020 ident: 10.1016/j.jtocrr.2023.100543_bib6 article-title: KRAS as a druggable target in NSCLC: rising like a phoenix after decades of development failures publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2020.101978 – volume: 9 start-page: 953 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib13 article-title: New horizons in KRAS-mutant lung cancer: dawn after darkness publication-title: Front Oncol doi: 10.3389/fonc.2019.00953 – volume: 384 start-page: 185 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib50 article-title: Distribution of KRAS G12C somatic mutations across race, sex, and cancer type publication-title: N Engl J Med doi: 10.1056/NEJMc2030638 – volume: 84 year: 2020 ident: 10.1016/j.jtocrr.2023.100543_bib11 article-title: KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2020.101974 – volume: 401 start-page: 733 year: 2023 ident: 10.1016/j.jtocrr.2023.100543_bib21 article-title: Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open- label, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(23)00221-0 – volume: 63 start-page: 52 year: 2020 ident: 10.1016/j.jtocrr.2023.100543_bib16 article-title: Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors publication-title: J Med Chem doi: 10.1021/acs.jmedchem.9b01180 – volume: 80 start-page: 2669 year: 2020 ident: 10.1016/j.jtocrr.2023.100543_bib4 article-title: The frequency of Ras mutations in cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-19-3682 – volume: 32 start-page: 1101 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib3 article-title: Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.06.001 – volume: 22 start-page: e856 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib31 article-title: Adverse overall survival impact of PD-L1 positivity in patients with KRAS G12C mutation is abolished by the immunotherapy publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2021.04.010 – volume: 30 start-page: 1653 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib32 article-title: Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression publication-title: Ann Oncol doi: 10.1093/annonc/mdz288 – volume: 14 start-page: 606 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib46 article-title: K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.12.013 – volume: 165 start-page: 28 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib5 article-title: Targeting KRAS G12C mutation in lung adenocarcinoma publication-title: Lung Cancer doi: 10.1016/j.lungcan.2021.12.021 – volume: 27 start-page: 2209 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib9 article-title: Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-4023 – volume: 33 start-page: S1417 issue: suppl year: 2022 ident: 10.1016/j.jtocrr.2023.100543_bib20 article-title: LBA10 - Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.08.051 – volume: 133 start-page: 144 year: 2019 ident: 10.1016/j.jtocrr.2023.100543_bib43 article-title: Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes publication-title: Lung Cancer doi: 10.1016/j.lungcan.2019.05.015 – volume: 24 start-page: 334 year: 2018 ident: 10.1016/j.jtocrr.2023.100543_bib44 article-title: Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-1841 – volume: 10 start-page: 54 year: 2020 ident: 10.1016/j.jtocrr.2023.100543_bib17 article-title: The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-19-1167 – volume: 19 start-page: 533 year: 2020 ident: 10.1016/j.jtocrr.2023.100543_bib1 article-title: RAS-targeted therapies: is the undruggable drugged? [published correction appears in Nat Rev Drug Discov. 2020;19:902] publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-020-0068-6 – volume: 4 year: 2022 ident: 10.1016/j.jtocrr.2023.100543_bib39 article-title: Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic NSCLC publication-title: JTO Clin Res Rep – volume: 24 start-page: 2371 year: 2013 ident: 10.1016/j.jtocrr.2023.100543_bib49 article-title: Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) publication-title: Ann Oncol doi: 10.1093/annonc/mdt205 – volume: 387 start-page: 120 year: 2022 ident: 10.1016/j.jtocrr.2023.100543_bib19 article-title: Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation publication-title: N Engl J Med doi: 10.1056/NEJMoa2204619 – volume: 9 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib29 article-title: Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer publication-title: J Immunother Cancer – volume: 159 start-page: 1 year: 2021 ident: 10.1016/j.jtocrr.2023.100543_bib48 article-title: A retrospective observational study of the natural history of advanced non–small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease publication-title: Lung Cancer doi: 10.1016/j.lungcan.2021.05.026 |
| SSID | ssj0002511782 |
| Score | 2.2751215 |
| Snippet | With the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is... AbstractIntroductionWith the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding... Introduction: With the approval of G12C inhibitors as the second line of treatment for KRAS G12C-mutated NSCLC, and the expanding research regarding targeting... |
| SourceID | doaj pubmedcentral proquest crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 100543 |
| SubjectTerms | (Chemo-)immunotherapy Hematology, Oncology, and Palliative Medicine Kirsten rat sarcoma KRAS G12C Non–small cell lung cancer Original |
| Title | Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666364323000863 https://www.clinicalkey.es/playcontent/1-s2.0-S2666364323000863 https://dx.doi.org/10.1016/j.jtocrr.2023.100543 https://www.proquest.com/docview/2862200315 https://pubmed.ncbi.nlm.nih.gov/PMC10477684 https://doaj.org/article/e2b410d0b0744501afb1ccd8601d50cc |
| Volume | 4 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDxUXBAXE8qiMxNUijvPysUT0BVuhbgu9WbZjs1tBgnazB34E_5kZJymJhLQcyDG242hmMvNN_HlMyBtrAIX7xLPKZ5YlADCYjLllTmOC7a12oeLN_CI7vU7Ob9Kb0VFfyAnrygN3gnvrYpPwqIoMxLokjbj2hltbFZBIVGlkLXrfSEajZAp9MALnPJwUBQEoYwLi7rBvLpC7btvGrrEcaCyQJ5AmYhKXQvn-SXgawc8peXIUjY4fkgc9jKRH3es_IvdcfUD25_1C-WPy69O6QQodNNOzP6Rx2nj64fJoQU94XNL5tluHp6uaanoJkJEFbk3owkKrqyjA0a-Onn2mF4vyY0nLZgmInV4h2ITWL6t2CTN839b9Vq6f-DQwPjraSvyEXB-_vypPWX_yArOAcFpmZVbZOM8rqTNeeCNdJKwTnnvOtUs05HRZLNMqkj420lSA27QDYFMA2Eyl8eIp2aub2j0jtJBauEI4760E_UnDcwNZsYMrFbJIZ0QMcle2L0uOp2N8UwP_7FZ12lKoLdVpa0bY3agfXVmOHf3foUrv-mJR7XADTE31pqZ2mdqMpINBqGHfKnhaeNBqx-T538a5Te8uNoqrTawitUBjRVuFvBBzzcnIHhF1SOcf5nw9WKwCh4GrQLp2zXajYlAdMhI5iL6YmPJEOtOWerUMpcexsAcu3T7_H_J8Qe7jG3eMvZdkr11v3SuAeK05DF_zYfj39hsW808I |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+Implication+of+KRAS+G12C+Mutation+in+a+Real-World+KRAS-Mutated+Stage+IV+NSCLC+Cohort+Treated+With+Immunotherapy+in+The+Netherlands&rft.jtitle=JTO+clinical+and+research+reports&rft.au=Noordhof%2C+Anneloes+L&rft.au=Swart%2C+Esther+M&rft.au=Damhuis%2C+Ronald+A+M&rft.au=Hendriks%2C+Lizza+E+L&rft.date=2023-09-01&rft.issn=2666-3643&rft.eissn=2666-3643&rft.volume=4&rft.issue=9&rft.spage=100543&rft_id=info:doi/10.1016%2Fj.jtocrr.2023.100543&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26663643%2Fcov200h.gif |